Abcam, ab265863, Human NDUFA13 (GRIM19) knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
NDUFA13 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 2 and 73 bp insertion in exon 2 and 8 bp deletion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 2 and 73 bp insertion in exon 2 and 8 bp deletion in exon 2,
Antibiotic resistance:Puromycin 1µg/mL,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-NDUFA13, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GRIM19 also known as NDUFA13 is a small protein with a molecular mass of approximately 16 kDa. It expresses mainly in mitochondria where it forms an integral component of the mitochondrial respiratory chain complex I. GRIM19 plays an important role in the functioning of complex I by facilitating the assembly and stabilization of the complex enabling efficient electron transport and ATP synthesis.
Biological function summary
GRIM19 interacts with several complexes and proteins within the mitochondrial inner membrane. As a part of complex I also known as NADH:ubiquinone oxidoreductase it contributes to the initial step of mitochondrial oxidative phosphorylation. GRIM19 also participates in the regulation of apoptosis and its expression is influenced during cellular stress situations highlighting its significance in cellular survival and energy production.
Pathways
GRIM19 integrates closely with mitochondrial apoptosis and energy metabolism pathways. Its interactions within oxidative phosphorylation place it in concert with both the electron transport chain and the apoptosis regulatory network. GRIM19 shares associations with related proteins such as cytochrome c oxidase and other complex I subunits highlighting its essential contribution to these important biological processes.
GRIM19 demonstrates links to various pathologies including cancer and mitochondrial diseases. Alterations in GRIM19 expression or function have been implicated in the progression of certain cancers such as colorectal and thyroid cancer where GRIM19's usual regulatory role in apoptosis can be disrupted. Additionally its involvement in mitochondrial disease connects to proteins like COX-A1 emphasizing the importance of maintaining functional complexes for cellular health.